View in EDS HTML Full Text PDF Full Text

Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir.

Saved in:
Bibliographic Details
Title: Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir.
Authors: Singh RSP; Pfizer Worldwide Research, Development and Medical, Cambridge, Massachusetts, USA., Toussi SS; Pfizer Worldwide Research, Development and Medical, Pearl River, New York, USA., Hackman F; Pfizer Worldwide Research, Development and Medical, Cambridge, UK., Chan PL; Pfizer Global Product Development, Sandwich, UK., Rao R; Pfizer Worldwide Research, Development and Medical, Cambridge, Massachusetts, USA., Allen R; Pfizer Worldwide Research, Development and Medical, Cambridge, Massachusetts, USA., Van Eyck L; Pfizer Clinical Research Unit, Brussels, Belgium., Pawlak S; Pfizer Clinical Research Unit, New Haven, Connecticut, USA., Kadar EP; Pfizer Worldwide Research, Development and Medical, Groton, Connecticut, USA., Clark F; Pfizer Worldwide Research, Development and Medical, Groton, Connecticut, USA., Shi H; Pfizer Global Product Development, Groton, Connecticut, USA., Anderson AS; Pfizer Worldwide Research, Development and Medical, Pearl River, New York, USA., Binks M; Pfizer Worldwide Research, Development and Medical, Cambridge, Massachusetts, USA., Menon S; Pfizer Worldwide Research, Development and Medical, Cambridge, Massachusetts, USA., Nucci G; Pfizer Worldwide Research, Development and Medical, Cambridge, Massachusetts, USA., Bergman A; Pfizer Worldwide Research, Development and Medical, Cambridge, Massachusetts, USA.
Source: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2022 Jul; Vol. 112 (1), pp. 101-111. Date of Electronic Publication: 2022 May 04.
Publication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535 (Electronic) Linking ISSN: 00099236 NLM ISO Abbreviation: Clin Pharmacol Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35388471
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Singh+RSP%22">Singh RSP</searchLink>; Pfizer Worldwide Research, Development and Medical, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Toussi+SS%22">Toussi SS</searchLink>; Pfizer Worldwide Research, Development and Medical, Pearl River, New York, USA.<br /><searchLink fieldCode="AU" term="%22Hackman+F%22">Hackman F</searchLink>; Pfizer Worldwide Research, Development and Medical, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Chan+PL%22">Chan PL</searchLink>; Pfizer Global Product Development, Sandwich, UK.<br /><searchLink fieldCode="AU" term="%22Rao+R%22">Rao R</searchLink>; Pfizer Worldwide Research, Development and Medical, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Allen+R%22">Allen R</searchLink>; Pfizer Worldwide Research, Development and Medical, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Van+Eyck+L%22">Van Eyck L</searchLink>; Pfizer Clinical Research Unit, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Pawlak+S%22">Pawlak S</searchLink>; Pfizer Clinical Research Unit, New Haven, Connecticut, USA.<br /><searchLink fieldCode="AU" term="%22Kadar+EP%22">Kadar EP</searchLink>; Pfizer Worldwide Research, Development and Medical, Groton, Connecticut, USA.<br /><searchLink fieldCode="AU" term="%22Clark+F%22">Clark F</searchLink>; Pfizer Worldwide Research, Development and Medical, Groton, Connecticut, USA.<br /><searchLink fieldCode="AU" term="%22Shi+H%22">Shi H</searchLink>; Pfizer Global Product Development, Groton, Connecticut, USA.<br /><searchLink fieldCode="AU" term="%22Anderson+AS%22">Anderson AS</searchLink>; Pfizer Worldwide Research, Development and Medical, Pearl River, New York, USA.<br /><searchLink fieldCode="AU" term="%22Binks+M%22">Binks M</searchLink>; Pfizer Worldwide Research, Development and Medical, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Menon+S%22">Menon S</searchLink>; Pfizer Worldwide Research, Development and Medical, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Nucci+G%22">Nucci G</searchLink>; Pfizer Worldwide Research, Development and Medical, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Bergman+A%22">Bergman A</searchLink>; Pfizer Worldwide Research, Development and Medical, Cambridge, Massachusetts, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220372741%22">Clinical pharmacology and therapeutics</searchLink> [Clin Pharmacol Ther] 2022 Jul; Vol. 112 (1), pp. 101-111. <i>Date of Electronic Publication: </i>2022 May 04.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0372741 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1532-6535 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200099236%22">00099236 </searchLink><i>NLM ISO Abbreviation: </i>Clin Pharmacol Ther <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35388471
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/cpt.2603
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 101
    Titles:
      – TitleFull: Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Singh RSP
      – PersonEntity:
          Name:
            NameFull: Toussi SS
      – PersonEntity:
          Name:
            NameFull: Hackman F
      – PersonEntity:
          Name:
            NameFull: Chan PL
      – PersonEntity:
          Name:
            NameFull: Rao R
      – PersonEntity:
          Name:
            NameFull: Allen R
      – PersonEntity:
          Name:
            NameFull: Van Eyck L
      – PersonEntity:
          Name:
            NameFull: Pawlak S
      – PersonEntity:
          Name:
            NameFull: Kadar EP
      – PersonEntity:
          Name:
            NameFull: Clark F
      – PersonEntity:
          Name:
            NameFull: Shi H
      – PersonEntity:
          Name:
            NameFull: Anderson AS
      – PersonEntity:
          Name:
            NameFull: Binks M
      – PersonEntity:
          Name:
            NameFull: Menon S
      – PersonEntity:
          Name:
            NameFull: Nucci G
      – PersonEntity:
          Name:
            NameFull: Bergman A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: 2022 Jul
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1532-6535
          Numbering:
            – Type: volume
              Value: 112
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Clinical pharmacology and therapeutics
              Type: main
ResultId 1